Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: J Clin Apher. 2023 Apr 12;38(5):514–521. doi: 10.1002/jca.22053

Table 2:

Patient characteristics and outcomes

PATIENT 1 PATIENT 2 PATIENT 3 PATIENT 4 PATIENT 5 PATIENT 6 PATIENT 7 PATIENT 8 PATIENT 9 PATIENT 10 PATIENT 11
Demographics 11yo female
51kg
14yo male
54kg
10yo male
41kg
4mo female
5kg
4yo female
15kg
8yo male
18.8kg
6yo male
26kg
12yo female
86.4kg
15yo female
55kg
7yo female
29kg
12 yo female
57.8kg
Pre-Transplant Diagnosis Dilated Cardiomyopathy Ischemic Cardiomyopathy Restrictive Cardiomyopathy Dilated cardiomyopathy Myocarditis s/p OHT, graft failure HLHS (MA/AA) Dilated cardiomyopathy Dilated cardiomyopathy HLHS (MA/AA) Dilated cardiomyopathy Dilated cardiomyopathy
Pre-Transplant Course ECMO x 10 days, Heartware LVAD x 6 days ECMO x 10 days, Heartware LVAD x 6 months Heartware LVAD x 6 months Berlin Heart LVAD x 5 weeks ECMO x 25 days, Berlin Heart BiVAD x 3 months Fontan Heartware LVAD x 5 months ECMO x 4 days, Heartware LVAD x 4 months Fontan HeartMate LVAD x 5 weeks Heartware LVAD x 10 months
Pre-TPE PRA 0% 27% 97% 0% 72% 68% 24% 65% 0% 11% 0%
Duration of Intraoperative TPE (min) 136 80 45 50 21 40 40 59 49 47 62
Plasma Volumes Processed 2.8 1.5 1.2 1.7 1.4 2.2 1.3 1.4 1.1 1.6 1.5
Transplant Crossmatch B cell and T cell compatible, no DSAs T cell compatible, B cell incompatible, no DSAs B cell and T cell incompatible, weakly positive DSA (A23, B49) T cell compatible, B cell compatible, no DSAs T cell compatible, B cell incompatible, no DSAs T cell compatible, B cell compatible, weakly positive DSA (A31, DR4) T cell incompatible, B cell compatible, no DSAs T cell compatible, B cell compatible, no DSAs T cell compatible, B cell compatible, weakly positive DSA (A2) T cell compatible, B cell compatible, no DSAs T cell compatible, B cell compatible, no DSAs
Additional TPE Performed None 6 4 None 5 8 None None 3 None None
Dates of Additional TPE POD#1 – POD#6 POD#1 – POD#5 POD#1 – POD#5 POD#19 – POD#22, POD#36-POD#38 POD#13, 14, 16
Indication for Additional TPE Weakly positive DSA (Bw6) on POD#4 Positive crossmatch 72% PRA Antibody mediated rejection Positive DSA (A2)
Latest DSA Negative 2 months post-transplant Negative 37 months post-transplant DQ8 (1:64) 39 months post-transplant Negative 37 months post-transplant Negative 5 days post-transplant A31 (1:16), DR4 (1:64) 5 weeks post-transplant Negative 12 months post-transplant Negative 11 months post-transplant Negative 7 months post-transplant Negative 2 months post-transplant Negative 1 month post-transplant
Outcome Deceased 2 months post-transplant due to pseudomonal sepsis Doing well 4 years post-transplant Stable chronic rejection 3 years post-transplant Doing well 37 months post-transplant Deceased 17 days post-transplant due to renal failure Deceased 7 weeks post-transplant due to AMR Doing well 14 months post-transplant Doing well 1 year post-transplant Doing well 10 months post-transplant Doing well 4 months post-transplant Doing well 1 month post-transplant

Abbreviations: ECMO: extracorporeal membranous oxygenation, LVAD: left ventricular assist device, BiVAD: biventricular assist device, HLHS: hypoplastic left heart syndrome, MA/AA: mitral atresia/aortic atresia, TPE: therapeutic plasma exchange, PRA: panel reactive antibodies, DSA: donor specific antigen, AMR: antibody mediated rejection

HHS Vulnerability Disclosure